Work

A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer

Year: 2009

Type: article

Abstract: PURPOSE: To investigate the activity of carboplatin and cetuximab in NSCLC. PATIENTS AND METHODS: This was a single arm, multicenter phase II trial, and the primary objective was response rate. RESULTS: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). CONCLUSION: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.

Source: Cancer Investigation

DOI: 10.3109/07357900903286958

Authors: Thomas E. Stinchcombe, Daniel S. Bradford, Thomas A. Hensing, Renato V. LaRocca, Mansoor Saleh, Tracey Evans, Kamal Bakri, Mark A. Socinski

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Highlands Oncology Group, Endeavor Health, Georgia Cancer Specialists, Abramson Cancer Center, University of Pennsylvania, Cape Fear Valley Health System, Cape Fear Valley Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2142335309

FWCI: 1.122

Cites: 36

Cited by: 8

Related to: 10